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Abstract
Background: Alpha-fetoprotein is produced by a variety of tumors such as hepatocellular carcinoma, hepatoblastoma,
and germ cell tumors of the ovary and testes. However, we present a case of significantly elevated serum
alpha-fetoprotein without evidence of malignant disease in a patient who is a carrier of chronic hepatitis B.
Case presentation: A 60-year-old Korean man presented with markedly increased alpha-fetoprotein (2350 ng/mL;
normal <5 ng/mL). Various diagnostic evaluations, including computed tomography of the abdomen and thorax
and ultrasonography of the abdomen and testes, showed liver cirrhosis and mild splenomegaly; however, no mass was
detected in the liver, testes, or other organs scanned. The laboratory findings showed elevated liver function, positivity for
hepatitis B e antigen, and a marked increase in hepatitis B virus deoxyribonucleic acid copy number (>7 × 105 IU/mL).
Our patient was diagnosed with acute exacerbation of chronic hepatitis B, and we presumed that this condition
might be related to extremely elevated alpha-fetoprotein. When our patient was treated with entecavir, the
serum alpha-fetoprotein level immediately decreased, in parallel with the hepatitis B virus deoxyribonucleic acid
copy number.
Conclusions: We report a rare case of extremely elevated alpha-fetoprotein due to acute exacerbation of chronic
hepatitis B without any malignancy, and a decrease in this tumor marker simultaneous with a decrease in hepatitis B
virus deoxyribonucleic acid copy number on entecavir treatment. This case report is important due to the rarity of the
case; furthermore, it provides details of a diagnostic process for a variety of benign diseases and malignant tumors that
should be considered in patients with elevated alpha-fetoprotein. Thus, we present a case report, along with a review,
that will be helpful for diagnosis and treatment of patients with elevated alpha-fetoprotein.
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Background
Serum tumor markers (STMs) are widely used in clinical
settings as effective indicators for screening of malignant
tumors, diagnosis of tumor type, establishing a prognosis,
analyzing treatment effects, and early detection of relapse.
Although the roles of STMs are limited in many cases,
owing to their varying sensitivity and specificity, when
STM values are markedly elevated, the corresponding can-
cer is strongly suspected [1]. In particular, alpha-fetoprotein
(α-FP) is a key marker in screening for liver cancer in high-
risk patient groups [2, 3].
Case presentation
A 60-year-old Korean man was admitted to our institu-
tion due to elevated α-FP discovered during a health
screening examination. He had been diagnosed with
chronic hepatitis B 6 years prior and received regular
follow-up observations; however, he had not been pres-
cribed any medication, as no abnormal findings associ-
ated with indicators of active hepatitis, cirrhosis, or liver
cancer were discovered. In addition, our patient had not
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received an abdominal ultrasound examination or a
blood test in the past 2 years.
Our patient showed a highly elevated α-FP level of
2350 ng/mL (normal; <5 ng/mL), along with elevated as-
partate aminotransferase (AST), 201 U/L (5–40 U/L),
alanine aminotransferase (ALT), 209 U/L (5–40 U/L),
total bilirubin, 1.91 mg/dL (0.2–1.2 mg/dL), direct bilirubin,
1.3 mg/dL, alkaline phosphatase, 100 U/L (35–123 U/L),
and gamma-glutamyl transpeptidase, (r-GTP) 256 U/L
(15–73 U/L). Our patient had no history of taking herbal or
traditional Korean medicines or western medicines, and no
history of infection or travel.
Although our patient was considered to be at high risk
for liver cancer because he was a carrier of chronic hepa-
titis B, no liver tumors were observed on the abdominal
ultrasound image; however, splenomegaly accompanied by
moderate cirrhosis was found. Interventional dynamic
computed tomography (CT) was performed on his chest,
abdomen, and pelvis for precision testing of the liver
parenchyma and assessment of cancers that typically show
elevated α-FP, such as testicular cancer and germ cell
cancer, along with paraneoplastic syndrome, which also
results in secretion of α-FP. However, the findings again
indicated only cirrhosis, as no tumor or lymphadenopathy
was observed in the liver parenchyma, chest, abdomen, or
pelvis. Moreover, there were no specific findings from a
precision urological physical examination and a testicular
ultrasound scan. In addition, gastric endoscopy was
performed to test for α-FP-secreting hepatoid gastric
adenocarcinoma, a common gastric cancer in Korea
that is known to have a poor prognosis; however, no malig-
nancy was detected. Other tumor markers, such as beta-
human chorionic gonadotropin (β-HCG) <1.20 mIU/mL
(0–1.25 mIU/mL), protein induced by vitamin K absence
or antagonist-II (PIVKA-II) 11 mAU (0–39 mAU), and
carcinoembryonic antigen (CEA) 2.8 ng/mL (0–5 ng/mL),
were all within the normal range.
Precision testing for hepatitis was performed because
our patient had a history of chronic hepatitis B and showed
elevated AST and ALT. The test results were hepatitis B
surface antigen positive (HBsAg+), hepatitis B e antibody
negative (HBsAb−), and hepatitis C virus antibody positive
(HCVAb−), and additional tests showed hepatitis B e anti-
gen positive (HBeAg+) and hepatitis B e antibody negative
(HBeAb−). Moreover, since our patient also showed a
marked elevation in hepatitis B virus deoxyribonucleic acid
(HBV DNA) copy number (>7 × 105 IU/mL), he was diag-
nosed with acute exacerbation of chronic hepatitis B.
Although it is extremely rare for α-FP to be elevated above
2000 ng/mL (normal; <5 ng/mL) due to acute hepatitis B,
there was a case study reporting decreased α-FP following
treatment for acute hepatitis B. Treatment for hepatitis B
was administered first and a follow-up imaging test was
scheduled for 2 months later.
After 1 month of entecavir treatment in our patient, his
AST/ALT and α-FP values (60/66 U/L and 762 ng/mL,
respectively) significantly decreased. For AST/ALT
and α-FP, these values further decreased to 53/47 U/L
and 370 ng/mL, respectively, after 2 months, and to
39/36 U/L and 163 ng/mL, respectively, after 3 months.
After treatment with entecavir, the HBV DNA copy num-
ber decreased to an immeasurable level after 3 months
and α-FP was normalized after 11 months (Fig. 1). CT
scans taken at 2 and 6 months of his chest, abdomen, and
pelvis, revealed no tumor mass or lymphadenopathy in
any solid organ, including his liver and testes. Currently,
our patient is in the second year of follow-up examination,
and normal levels of α-FP and HBV DNA copy number
have been maintained, and no evidence of a malignant
tumor has been found in any of the imaging tests (Fig. 1).
Fig. 1 After taking the entecavir, α-fetoprotein and aspartate aminotransferase were gradually decreased
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Discussion
Tumor markers include various hormones, enzymes, and
antigens secreted into the bloodstream by malignant tu-
mors. Because these tumor markers can be used in simple
blood tests to screen for malignant tumors, diagnose can-
cer type, provide a prognosis, analyze treatment effects,
and provide early detection of relapse, they are in wide
clinical use, despite their many limitations such as varia-
tions in sensitivity and specificity. Especially in people
without signs or symptoms of tumors, assessing the levels
of prostate-specific antigen (PSA) for prostate cancer, can-
cer antigen 125 (CA125) for ovarian cancer, and alpha-
fetoprotein (α-FP) for hepatocellular carcinoma (HCC) is
used as a minimally invasive screening test using blood
samples [1].
Among these, α-FP is a glycoprotein secreted by fetal
cells during the embryonic stage and in some malignant
diseases. In 1944, Pederson first discovered a fetus-specific
serum, and in 1964, Tatarino reported α-FP in the serum
of a patient with hepatocytic cancer. Ruoslahti et al. puri-
fied human α-FP in 1971 and developed a radioimmuno-
assay technique to quantify it, which has since been used
in clinical settings. Currently, α-FP is traditionally and
widely used as a tumor marker for HCC. However, the
sensitivity and specificity for using α-FP to detect HCC is
only in the range of 41–65 % and 80–90 %, respectively,
as serum α-FP is normal in up to 35 % of small hepatocel-
lular carcinoma cases [2–4].
Several tools used alone or in combination with α-FP
have been evaluated, as there are many different views re-
garding the use of α-FP as a biomarker. For example, a re-
cent Japanese guideline indicates the combined use of
tumor markers (α-FP >200 ng/mL, α-FP -L3 >15 %, or
PIVKA-II >40 mAU/mL) for the diagnosis of HCC [5]. On
the contrary, α-FP is considered to be a feasible tool for
screening and early diagnosis in China as more than 60 %
of HCC patients have an α-FP level of >400 ng/ml [6].
Although α-FP is widely known as a major marker for
primary liver cancer, it is also known to increase with a
variety of other diseases such as various malignant tumors,
hepatic necrosis, acute hepatitis, colitis, and gynecological
diseases [1]. Generally, when α-FP is elevated but no
tumor can be detected through imaging, a regular follow-
up observation is conducted with regular monitoring of
progress. However, when the α-FP value is markedly ele-
vated, as seen in the current case, additional imaging tests
are performed on the liver because the possibility of ma-
lignant tumor cannot be excluded. Other cancers must be
also considered; however, no report has been published
outlining which cancers should be suspected or the extent
to which an examination should be conducted [2].
As the name fetoprotein indicates, levels of this protein
are elevated during pregnancy, but can also be elevated,
along with ß-human chorionic gonadotropin (ß-HCG),
in ovarian, endometrial, testicular, and extragonadal
germ cell cancers, depending on gender. Therefore, in
addition to testing for serum ß-HCG and imaging the uro-
reproductive system, a close examination by a urologist or
gynecologist is necessary. In particular, extragonadal germ
cell tumors often develop in the retroperitoneum and
mediastinum, whereas teratomas are observed in a variety
of areas, and have been reported to become more frequent
following lung cancer; hence, chest imaging is also required
[1, 7]. In Korea, which has an especially high prevalence of
gastric cancer, the prevalence of hepatoid adenocarcinoma
of the stomach, which produces high levels of α-FP and
looks similar to primary liver cancer, is known to be low
(0.3–1 %). However, since its prognosis is known to be ex-
tremely poor, because of its high rate of metastasis to the
liver and other organs before diagnosis, a gastroscopy may
be necessary [8].
Few cases have been reported in which α-FP was ele-
vated without any evidence of a malignant tumor; how-
ever, studies have reported values elevated to 2002 ng/mL
in young patients with autoimmune hepatitis, and up to
371.51 ng/mL in adults with cavernous hemangioma
[9, 10].
A case similar to the current case, in which α-FP was
elevated to >2000 ng/mL due to acute exacerbation of
hepatitis, but normalized following anti-viral therapy, as
well as a few other cases have been reported internation-
ally. However, cases like these are extremely rare, and
even in the above-mentioned cases, the authors only dis-
cussed proof for the absence of liver cancer and the
treatment process for acute hepatitis; they did not dis-
cuss ruling out other diseases that could have potentially
increased α-FP [11–13].
Conclusions
Here, we present a case of α-FP elevation due to acute
exacerbation of chronic hepatitis without any evidence
of a malignant tumor, along with a literature review.
This case report is important because of the rarity of
the case, and provides details of a diagnostic process for
benign diseases (acute hepatitis and hemangioma) and
malignant tumors (testicular cancer, germ cell tumors,
hepatocellular carcinoma, and gastric adenocarcinoma)
that should be considered in patients with elevated α-FP.
We believe that the findings presented in this report will
be helpful for the diagnosis and treatment of patients
with elevated α-FP.
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